Longwood Healthcare Leaders 春季會(huì)議以麻省理工學(xué)院Koch研究所為中心，通過(guò)網(wǎng)絡(luò)會(huì)議邀請(qǐng)生物制藥公司的首席執(zhí)行官、研發(fā)負(fù)責(zé)人、及頂級(jí)學(xué)術(shù)研究人員參加，共同商討，促進(jìn)藥物研發(fā)的轉(zhuǎn)化，造福病人！會(huì)議由諾貝爾獎(jiǎng)獲得者，Biogen/Alnylam 聯(lián)合創(chuàng)始人 Phil Sharp 共同主持。會(huì)議僅限受邀參加。

Longwood Healthcare Leaders Spring Meeting centered on MIT’s Koch Institute via web-conference with leading bio-pharma CEOs, heads of R&D, top academic researchers, and healthcare investors, co-hosted by Nobel laureate and Biogen/Alnylam co-founder Phil Sharp. Longwood Healthcare Leaders Meetings drive transparency and collaboration in order to accelerate the translation of discoveries into medicines to help patients. Meetings are invitation-only.

美迪西創(chuàng)始人兼CEO陳春麟博士將參加此次大會(huì)，并在5月4日上午 9:50 （美東時(shí)間）與 Raj Devraj (Rectify Pharmaceuticals公司CEO), Bill Hinshaw (Axcella Therapeutics 公司CEO),  Peter Lebowitz (Janssen 全球腫瘤治療領(lǐng)域負(fù)責(zé)人), Reenie McCarthy (Stealth BioTherapeutics 公司CEO)， Chen Schor (Adicet Bio 公司CEO)一起進(jìn)行嘉賓討論，主題為“Expediting Research for Treatment and Cures”。

Dr. Chun-Lin Chen, founder & CEO of Medicilon, will participate in the panel discussion titled "Expediting Research for Treatment and Cures" on May 4 at 9:50 am ET. The other invited participants are Raj Devraj (CEO, Rectify Pharmaceuticals), Bill Hinshaw (CEO, Axcella Therapeutics), Peter Lebowitz (Global Oncology Therapeutic Area Head, Janssen), and Reenie McCarthy (CEO, Stealth BioTherapeutics). The panel discussion is moderated by Chen Schor (CEO, Adicet Bio).

陳春麟博士、美國(guó)商務(wù)發(fā)展副總裁 Stephen Grant及美國(guó)商務(wù)團(tuán)隊(duì)將于 5 月 5 日下午 5:00-7:00（美東時(shí)間）參加 Garden Party。屆時(shí)將與參會(huì)的眾嘉賓進(jìn)行詳細(xì)交談，共同探討我們的專業(yè)服務(wù)如何更快地加速各企業(yè)的藥物研發(fā)過(guò)程！

Dr. Chun-Lin Chen and Medicilon VP of US Business Development Dr. Stephen Grant together with our US Business Development team will be joining the Garden Party on MAY 5 at 5:00-7:00 pm ET. We are looking forward to meeting you in this party to discuss how our services and capabilities would support your research needs and expedite your drug discovery and development programs. Wish you a safe trip!

美迪西是一家專業(yè)的生物醫(yī)藥臨床前綜合研發(fā)服務(wù)CRO，為全球的醫(yī)藥企業(yè)和科研機(jī)構(gòu)提供全方位的符合國(guó)內(nèi)及國(guó)際申報(bào)標(biāo)準(zhǔn)的一站式新藥研發(fā)服務(wù)。我們關(guān)注全球醫(yī)藥行業(yè)創(chuàng)新發(fā)展的需求，立足于創(chuàng)新藥物研發(fā)的關(guān)鍵環(huán)節(jié)，憑借服務(wù)國(guó)內(nèi)外生物醫(yī)藥行業(yè)所積累的經(jīng)驗(yàn)，構(gòu)建涵蓋藥物發(fā)現(xiàn)、藥學(xué)研究以及臨床前研究關(guān)鍵技術(shù)的綜合性技術(shù)平臺(tái)，為全球生物醫(yī)藥行業(yè)提供全方位新藥臨床前研發(fā)服務(wù)。至2021年報(bào)告期末，美迪西已為全球超過(guò)1460家客戶提供新藥研發(fā)服務(wù)，參與研發(fā)完成的新藥項(xiàng)目有221件IND獲批臨床，與國(guó)內(nèi)外優(yōu)質(zhì)客戶共同成長(zhǎng)。美迪西將繼續(xù)立足全球視野，聚力中國(guó)創(chuàng)新，為人類健康貢獻(xiàn)力量！

Medicilon is an integrated contract research organization (CRO), providing comprehensive one-step new drug R&D for pharmaceutical enterprises and scientific research institutions around the world. With our experience in serving domestic and foreign biomedical industries, we have built an integrated technical platform covering key technologies in drug discovery, pharmaceutical research, and preclinical research, in a bid to provide comprehensive preclinical new drug R&D for the global biomedical industry.

18⁺

18⁺ years of experience in new drug R&D
18⁺年新藥研發(fā)經(jīng)驗(yàn)

1460⁺

Active clients worldwide
全球范圍內(nèi)活躍客戶

2440⁺

Newdrug discovery scientists and service personnel新藥研發(fā)科學(xué)家及研發(fā)服務(wù)人員

74000⁺

Square meters of Laboratory floor space
研發(fā)實(shí)驗(yàn)室

221

Projects successfully approved with NMPA, FDA, EMA, and TGA
221件IND在 NMPA、FDA、EMA 和 TGA 成功獲批

聯(lián)系我們：

郵箱：marketing@medicilon.com.cn

電話: +86 (21) 5859-1500（總機(jī)）